BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Vote In favor of Your Favored Web-based Visual depiction Administration - 2How a rare drug made from scientists' blood saves babies from botulism
- 3Police break up illegal chicken slaughter in Germany
- 4Reporter's Notebook: The Post embeds with foreign armies visiting the IDF
- 5Former Peruvian President Pedro Castillo sentenced for conspiracy
- Steinmeier honours Italian 'guest workers' who rebuilt German economy
- From Modesty to Administration: Self-improvement in Interactive abilities
- A Timeline of Rising Antisemitism in Australia
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Solar storms can trigger auroras on Earth. This star’s explosion could destroy a planet’s atmosphere
- Public Parks in the USA
- Vote in favor of Your Number one BWM Vehicles
- Watch live as near-Earth asteroid Eros buzzes the Andromeda Galaxy on Nov. 30 (video)
- 3 Must-Change Settings for iPhone Clients: Safeguard Yourself !
